FP:DBV DBV Technologies S.A
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage product development programs include treatments for Crohn's disease and respiratory syncytial virus. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.This company has ADRs that trade in the U.S. as the symbol DBVT.
3.00 EUR
As of 03/24/2023
Security Information
Category1: Global Equity
Category2: Common stocks
Category3: Developed markets ex-US
GICS sector: Health Care
Industry: Biotechnology
Index country: France
Country of incorporation: France
IPO date: 03/28/2012
Stock exchange: Euronext Paris
Exchange country: France
Market cap: 148,760,560 EUR
Current dividend yield: 0.00%
Sedol: B59DTF2